24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults with Type 2 Diabetes Mellitus - News Press Release | PharmiWeb.com
Links shared publicly online about this topic.
- 860total visits
24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults with Type 2 Diabetes Mellitus - News Press Release | PharmiWeb.com
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing gl
View full resource at pharmiweb.com
Tags: Diabetes Type 2 Medication, Diabetes Medication, Drug, Phase 3 Clinical Trial, AstraZeneca, Bristol-Myers Squibb
Most Recently Shared on September 24, 2010 at 1:52 pm By:
Press Release: Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a... http://bit.ly/9IP0js
Advertisement
